Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP3 in combination with chemotherapy and nivolumab in head and neck cancer
NCT05743270Phase 2Withdrawn
- Sponsor
- Replimune Group, Inc.
- Start
- Jan 2024
- Primary completion
- Mar 2026
- Modality
- Oncolytic Viruses
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of RP3 in squamous cell carcinoma of the head and neck (HNSCC) (3 arms), sponsored by Replimune Group, Inc. Primary endpoints: Progression-free Survival up to 3 years and Objective Response Rate up to 3 years. Planned start Jan 2024; status: withdrawn.
02
Drugs
RP3
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05743270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05743270.